Hyperprolactinaemia is a common side effect of antipsychotics; markedly raised levels are less common. Higher levels of prolactin result from longer exposure to higher doses, especially with older antipsychotics or with risperidone, sulpiride or amisulpride. Galactorrhoea, gynaecomastia, menstrual abnormalities and sexual dysfunction including hypogonadism and fertility problems are consequences of raised prolactin, and in the longer-term bone demineralisation. Younger patients may be more susceptible to hyperprolactinaemia. Trial reports often fail to state the frequency of raised levels.
AbelKMHeatlieHF. (2008) Sex and age specific incidence of fractures in mental illness: an historical population-based cohort study. J Clin Psychiatry69: 1398–1403.
2.
AichhornWMarksteinerJWalchT. (2007) Age and gender effects on olanzapine and risperidone plasma concentrations in children and adolescents. J Child Adolesc Psychopharmacol17: 665–674.
3.
AlexiadisMWhitehornDWoodleyH. (2002) Prolactin elevation with quetiapine. Am J Psychiatry159: 1608–1609.
4.
AlfaroCLWudarskyMNicolsonR. (2002) Correlation of antipsychotic and prolactin concentrations in children and adolescents acutely treated with haloperidol, clozapine, or olanzapine. J Child Adolesc Psychopharmacol12: 83–91.
5.
ArakawaROkumuraMItoH. (2010) Positron emission tomography measurement of dopamine D2 receptor occupancy in the pituitary and cerebral cortex: relation to antipsychotic-induced hyperprolactinemia. J Clin Psychiatry71: 1131–1137.
6.
AstonJRechsteinerEBullN. (2010) Hyperprolactinaemia in early psychosis—not only due to antipsychotics. Prog Neuropsychopharmacol Biol Psychiatry34: 1342–1344.
7.
BaptistaTLaCruzAMezaT. (2001) Antipsychotic drugs and obesity: Is prolactin involved?Can J Psychiatry46: 829–834.
8.
BerwaertsJCletonARossenuS. (2010) A comparison of serum prolactin concentrations after administration of paliperidone extended-release and risperidone tablets in patients with schizophrenia. J Psychopharmacol24: 1011–1018.
9.
BillerBMKBaumHBRosenthalDI. (1992) Progressive trabecular osteopenia in women with hyperprolactinemic amenorrhea. J Clin Endocrinol Metab75: 692–697.
10.
BillerBMCoughlinJFSaxeV. (1991) Osteopenia in women with hypothalamic amenorrhea: a prospective study. Obstet Gynecol78: 996–1001.
11.
BuhagiarKCassarJR (2008) Prolactin levels during long-term risperidone treatment in children and adolescents: a cross-sectional study. German Journal of Psychiatry11: 45–50.
BusheCShawM (2007) Prevalence of hyperprolactinaemia in a naturalistic cohort of schizophrenia and bipolar outpatients during treatment with typical and atypical antipsychotics. J Psychopharmacol21: 768–773.
14.
BusheCYeomansDFloydT. (2008) Categorical prevalence and severity of hyperprolactinaemia in two UK cohorts of patients with severe mental illness during treatment with antipsychotics. J Psychopharmacol22: 56–62.
15.
ByerlyMSuppesTTranQV. (2007) Clinical implications of antipsychotic-induced hyperprolactinemia in patients with schizophrenia spectrum or bipolar spectrum disorders: recent developments and current perspectives. J Clin Psychopharmacol27: 639–661.
16.
CooksonJC (1981) Oestrogens, dopamine and mood. Br J Psychiatry139: 365–366.
17.
CooksonJCKennedyNMGribbonD (1986) Weight gain and prolactin levels in patients on long-term antipsychotic mediation: a double-blind trial of haloperidol decanoate and fluphenazine decanoate. Int Clin Psychopharmacol1: 41–51.
18.
CooksonJCMoultPJA. (1983) The relationship between prolactin levels and clinical ratings in manic patients treated with oral and intravenous test doses of haloperidol. Psychol Med13: 279–285.
19.
CooksonJCSilverstoneTReesL H (1982) Plasma prolactin and growth hormone levels in manic patients treated with pimozide. Br J Psychiatry140: 274–280.
20.
Di SommaCColaoADi SarnoA. (1998) Bone marker and bone density responses to dopamine agonist therapy in hyperprolactinemic males. J Clin Endocrinol Metab83: 807–813.
21.
Fernandez-EgeaEOliveiraCJusticiaA. (2012) Prolactin concentrations in newly diagnosed, antipsychotic-naïve patients with nonaffective psychosis. Schizophr Res, 134, 16–19.
22.
GreenAIFaraoneSVBrownWA (1990) Prolactin shifts after neuroleptic withdrawal. Psychiatr Res32: 213–219.
23.
GreggCShikarVLarsenP. (2007) White matter plasticity and enhanced remyelination in the maternal CNS. J Neurosci27: 1812–1823.
24.
GruenPHSacharE JLangerG. (1978) Prolactin responses to neuroleptics in normal and schizophrenic subjects. Arch Gen Psychiatry35:106–116.
25.
HaasMEerdekensMKushnerS. (2009) Efficacy, safety and tolerability of two risperidone dosing regimens in adolescent schizophrenia: double-blind study. Br J Psychiatry194: 158–164.
26.
HaddadPMWieckA (2004) Antipsychotic-induced hyperprolactinaemia: Mechanisms, clinical features and management. Drugs64: 2291–2314.
27.
HalbreichUKahnLS (2003) Hyperprolactinemia and schizophrenia: Mechanisms and clinical aspects. J Psychiatr Pract9: 344–353.
28.
HaneyEMWardenSJ (2008) Skeletal effects of serotonin (5-hydroxytryptamine) transporter inhibition: evidence from clinical studies. J Musculoskelet Neuronal Interact8: 133–145.
29.
HarveyPWEverettDJSpringallCJ (2008) Adverse effects of prolactin in rodents and humans: breast and prostate cancer. J Psychopharmacol22: 20–27.
30.
HayIDWassJAH (2008) Clinical endocrine oncology. John Wiley & Sons. 238.
31.
Hippisley-CoxJVinogradovaYCouplandC. (2007) Risk of malignancy in patients with schizophrenia or bipolar disorder: nested case-control study. Arch Gen Psychiatry64: 1368–1376.
32.
HowardLKirkwoodGLeeseM (2007) Risk of hip fracture in patients with a history of schizophrenia. Br J Psychiatry190: 129–134.
33.
HowesODWheelerMJPilowskyLS. (2007) Sexual function and gonadal hormones in patients taking antipsychotic treatment for schizophrenia or schizoaffective disorder. J Clin Psychiatry3: 361–367.
34.
KahnRSFleischhackerWWBoterH. (2008) Effectiveness of antipsychotic drugs in first episode schizophrenia and schizophreniform disorder: an open randomised clinical trial. Lancet371: 1085–1097.
35.
KapurSLangloisXVinkenP. (2002) The differential effects of atypical antipsychotics on prolactin elevation are explained by their differential blood-brain disposition: a pharmacological analysis of results in rats. J Pharmacol Exp Ther302: 1129–-1134.
36.
KapurSZipurskyRJonesC. (2000) A positron emission tomography study of quetiapine in schizophrenia: a preliminary finding of an antipsychotic effect with only transiently high dopamine D2 receptor occupancy. Arch Gen Psychiatry57: 553–559.
37.
KellyDLConleyRR (2006) A randomized double-blind 12-week study of quetiapine, risperidone or fluphenazine on sexual functioning in people with schizophrenia. Psychoneuroendocrinology31: 340–346.
38.
KishimotoTWatanabeKShimadoN. (2008) Antipsychotic-induced hyperprolactinemia inhibits the hypothalamo-pituitary-gonadal axis and reduces bone mineral density in male patients with schizophrenia. J Clin Psychiatry69: 385–391.
39.
KlibanskiANeerRMBeitinsIZ. (1980) Decreased bone density in hyperprolactinemic women. N Engl J Med303: 1511–1514.
40.
KnegteringCasteleinSBousH. (2004) A randomized open-label study of the impact of quetiapine versus risperidone on sexual functioning. J Clin Psychopharmacol24: 56–61.
41.
KuruvillaAPeedicayilJSrikrishnaG. (1992) A study of serum prolactin levels in schizophrenia: comparison of males and females. Clin Exp Pharmacol Physiol19: 603–606.
42.
LangerGSacharEJHalpernFS. (1977a) The prolactin response to neuroleptic drugs. A test of dopaminergic blockade: neuroendocrine studies in normal man. J Clin Endocrinol Metab45: 996–1002.
43.
LangerGSacharEJGruenPH. (1977b) Human prolactin responses to neuroleptic drugs correlate with antischizophrenic potency: dopamine hypothesis supported in man. Nature266: 639–640.
44.
LeuchtSBurkardTHendersonJH. (2007) Physical illness and schizophrenia. Cambridge: Cambridge Press.
45.
LiebermanJAStroupTSMcEvoyJP. (2005) Clinical antipsychotic trials of intervention effectiveness (CATIE)investigators: Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med353:1209–1223.
46.
LinCHHuangKHChangYC. (2011) Clozapine protects bone mineral density in female patients with schizophrenia. Int J Neuropsychopharmacol. Epub ahead of print 10 October 2011.
47.
Lopez-RodrıguezRRomanMNovalbosJ. (2011) DRD2 Taq1A polymorphism modulates prolactin secretion induced by atypical antipsychotics in healthy volunteers. J Clin Psychopharmacol31: 555–562.
48.
MackinPWatonANulkarA. (2011). Prolactin and smoking status in antipsychotic-treated patients. J Psychopharmacol25: 698–703.
49.
MalikPKemmlerGHummerM. (2011). Sexual dysfunction in first-episode schizophrenia patients: results from european first episode schizophrenia trial. J Clin Psychopharmacol: 31, 274–280.
50.
ManciniTCasanuevaFFGiustinaA (2008) Hyperprolactinemia and prolactinomas. Endocrinol Metab Clin North Am37: 67–99.
51.
McEvoyJPLiebermanJAPerkinsDO. (2007) Efficacy and tolerability of olanzapine, quetiapine, and risperidone in the treatment of early psychosis: a randomized, double-blind 52- week comparison. Am J Psychiatry164: 1050–1060.
52.
McEvoyJPLiebermanJAStroupTS. (2006) Effectiveness of clozapine versus olanzapine, quetiapine, and risperidone in patients with chronic schizophrenia who did not respond to prior atypical antipsychotic treatment. Am J Psychiatry163: 600–610.
53.
McIlhinneySSmithM (2008) Depot risperidone, hyperprolactinaemia and prolactin-associated side effects. Psychiatr Bull32: 358–359.
54.
MelmedSJamesonJL (2005) Disorders of the anterior pituitary and hypothalamus. In: JamesonJNKasperDLHarrisonTRetal. (eds) Harrison’s principles of internal medicine. New York: McGraw-Hill Medical Publishing Division.
55.
MeltzerHYGoodeDSchyvePM. (1979) Effect of clozapine on human serum prolactin levels. Am J Psychiatry136: 1550–1555.
56.
MirAShivakumarKWilliamsonRJ. (2008) Change in sexual dysfunction with aripiprazole: a switching or add-on study. J Psychopharmacol22: 244–253.
57.
MontgomeryJWinterbottomEJessaniM. (2004) Prevalence of hyperprolactinemia in schizophrenia: association with typical and atypical antipsychotic treatment. J Clin Psychiatry65: 1491–1498
58.
NakoneznyPAByerlyMJRushA J (2007) The relationship between serum prolactin level and sexual functioning among male outpatients with schizophrenia or schizoaffective disorder: a randomized double-blind trial of risperidone vs. quetiapine. J Sex Marital Ther33: 203–216.
59.
National Institute for Health and Clinical Excellence (NICE) (2007) The management of bipolar disorder in adults, children and adolescents, in primary and secondary care. National Clinical Practice Guideline Number 38 commissioned by the National Collaborating Centre for Mental Health published by The British Psychological Society and Gaskell. (www.nice.org.uk).
60.
National Institute for Health and Clinical Excellence (NICE) (2009) NICE clinical guideline 82. Schizophrenia: Core interventions in the treatment and management of schizophrenia in adults in primary and secondary care. Update of NICE clinical guideline 1. (www.nice.org.uk).
61.
O’KeaneV (2008) Antipsychotic-induced hyperprolactinaemia, hypogonadism and osteoporosis in the treatment of schizophrenia. J Psychopharmacol22: 70–75.
62.
PappagalloMSilvaR (2004). The effect of atypical antipsychotic agents on prolactin levels in children and adolescents. J Child Adolesc Psychopharmacol14: 359–371.
63.
Perez-IglesiasRCrespo-FacorroBAmodoJA. (2007) A 12 week randomized clinical trial to evaluate metabolic changes in drug naïve, first-episode psychosis patients treated with haloperidol, olanzapine, or risperidone. J Clin Psychiatry68: 1733–1740.
PoyrazBCAksoyCBalcioğluI (2008) Increased incidence of autoimmune thyroiditis in patients with antipsychotic-induced hyperprolactinemia. Eur Neuropsychopharmacol18: 667–672.
66.
RaoVABishopMCoppenA (1980) Clinical state, plasma levels of haloperidol and prolactin: a correlation study in chronic schizophrenia. Br J Psychiatry137: 518–521.
67.
RichTD (1984) Sulpiride: assessment of a pharmacologically and chemically distinct neuroleptic. Med Hypotheses14: 69–81.
68.
RobinsonDGWoernerMGNapolitanoB. (2006) Randomized comparison of olanzapine versus risperidone for the treatment of first-episode schizophrenia: 4-month outcomes. Am J Psychiatry163: 2096–2102.
69.
RokeYvan HartenPN. (2009) Antipsychotic medication in children and adolescents: A descriptive review of the effects on prolactin level and associated side effects. J Child Adolesc Psychopharmacol19: 403–414.
70.
RosenCJ (2009) Serotonin rising – The bone, brain, bowel connection. N Engl J Med360: 957–959.
71.
RybakowskiJKDmitrzak-WeglarzM. (2012) Functional –1149 G/T polymorphism of the prolactin gene in schizophrenia. Neuropsychobiology65: 41–44.
72.
SaitoECorrellCUGallelliK. (2004) A prospective study of hyperprolactinaemia in children and adolescents treated with atypical antipsychotic agents. J Child Adolesc Psychopharmacol14: 350–358.
73.
SchoolerNRabinowitzJDavidsonM. (2005) Risperidone and haloperidol in first-episode psychosis: A long-term randomized trial. Am J Psychiatry162: 947–953.
74.
SerriOChikCLUrE. (2003) Diagnosis and management of hyperprolactinemia. CMAJ169: 575–581.
75.
ShimJ-CShinJ-G KKellyDL. (2007) Adjunctive treatment with a dopamine partial agonist, aripiprazole, for antipsychotic-induced hyperprolactinemia: A placebo-controlled trial. Am J Psychiatry164: 1404–1410.
76.
SikichLFrazierJAMcClellanJ. (2008) Double-blind comparison of first- and second-generation antipsychotics in early-onset schizophrenia and schizoaffective disorder: findings from the Treatment of Early-Onset Schizophrenia Spectrum Disorders (TEOSS) Study. Am J Psychiatry165: 1420–1431.
77.
SilverstoneCookson (1983) Examining the dopamine hypotheses of schizophrenia and of mania using the prolactin response to antipsychotic drugs. Neuropharmacology22: 539–541.
78.
SlatteryDANeumannID (2008) Prolactin is involved in maternal behaviour and stress related alterations in the HPA axis. J Physiol586: 377-385.
79.
SmithS (2008) The impact of hyperprolactinaemia on sexual function in patients with psychosis. J Psychopharmacol22: 63-69.
80.
StevenaertABeckersAVandalemJL. (1986) Early normalization of luteinizing hormone pulsatility after successful transsphenoidal surgery in women with microprolactinomas. J Clin Endocrinol Metab62: 1044–1047.
81.
StevensJRKymissisPIBakerAJL (2005) Elevated prolactin levels in male youths treated with risperidone and quetiapine. J Child Adolesc Psychopharmacol15: 893–900.
82.
StroupTSLiebermanJAMcEvoyJP. (2006) Effectiveness of olanzapine, quetiapine, risperidone, and ziprasidone in patients with chronic schizophrenia following discontinuation of a previous atypical antipsychotic. Am J Psychiatry163: 611–622.
83.
StroupTSLiebermanJAMcEvoyJP. (2007) Effectiveness of olanzapine, quetiapine, and risperidone in patients with chronic schizophrenia after discontinuing perphenazine: A CATIE study. Am J Psychiatry164: 415–427.
84.
SugawaraNYasui-FurukoriNFujiiA. (2011) No association between bone mass and prolactin levels among patients with schizophrenia. Human Psychopharmacology: Clinical and Experimental26: 596–601.
85.
SvestkaJSynekOTomanováJ. (2007) Differences in the effect of second-generation antipsychotics on prolactinaemia: six weeks open-label trial in female in-patients. Neuro Endocrinol Lett28: 881–888.
86.
SzarfmanATonningJLevineJG. (2006) Atypical antipsychotics and pituitary tumours: a pharmacovigilance study. Pharmacotherapy26: 748–758.
87.
TohenMKryzhanovskayaLCarlsonG. (2007) Olanzapine versus placebo in the treatment of adolescents with bipolar mania. Am J Psychiatry164: 547–1556.
88.
TurronePKapurSSeemanMV. (2002) Elevation of prolactin levels by atypical antipsychotics. Am J Psychiatry159: 133–135.
89.
TworogerSEliassenHSlussP. (2007) A prospective study of plasma prolactin concentrations and the risk of premenopausal and postmenopausal breast cancer. J Clin Oncol25: 1–7.
90.
TworogerSSSlussPHankinsonSE (2006) Association between plasma prolactin concentrations and risk of breast cancer among predominantly premenopausal women. Cancer Res66: 2476–2482
91.
WangPSWalkerAMTsuangMT. (2002) Dopamine antagonists and the development of breast cancer. Arch Gen Psychiatry59: 1147–1154.
92.
WilesDFranklinMDenckerS J. (1980) Plasma fluphenazine and prolactin levels in schizophrenic patients during treatment with low and high doses of fluphenazine enanthate. Psychopharmacology (Berl)71: 131–136.
93.
WudarskyMNicolsonRHamburgerSD. (1999) Elevated prolactin in pediatric patients on typical and atypical antipsychotics. J Child Adolesc Psychopharmacol9: 239–245.
94.
Yasui-FurukoriNFujiiASugawaraN. (2012) No association between hormonal abnormality and sexual dysfunction in Japanese schizophrenia patients treated with antipsychotics. Human Psychopharmacology: Clinical and Experimental, 27: 82–89.
95.
YoungRLawfordBRBarnesM. (2004) Prolactin levels in antipsychotic treatment of patients with schizophrenia carrying the DRD2*A1 allele. Br J Psychiatry185: 147–151.
96.
ZhangXRZhangZJZhuRX. (2011) Sexual dysfunction in male schizophrenia: influence of antipsychotic drugs, prolactin and polymorphisms of the dopamine D2 receptor genes. Pharmacogenetics12: 1127–1136.
97.
ZipurskyRBGuHGreenAI. (2005) Course and predictors of weight gain in people with first-episode psychosis treated with olanzapine or haloperidol. Br J Psychiatry187: 537–543.
